Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

P. Basova, V. Pospisil, F. Savvulidi, P. Burda, K. Vargova, L. Stanek, M. Dluhosova, E. Kuzmova, A. Jonasova, U. Steidl, P. Laslo, T. Stopka,

. 2014 ; 33 (39) : 4735-45.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008546
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do 2017-12-31
Open Access Digital Library od 1997-01-01
Medline Complete (EBSCOhost) od 1997-01-09 do 2015-11-26
Health & Medicine (ProQuest) od 1997-01-01 do 2017-12-31
Public Health Database (ProQuest) od 1997-01-01 do 2019-12-31

Odkazy

PubMed 24121269
DOI 10.1038/onc.2013.414
Knihovny.cz E-zdroje

PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1(ure/ure) mice (PU.1(ure/ure)p53(-/-)) results in more aggressive AML with shortened overall survival. PU.1(ure/ure)p53(-/-) progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1(ure/ure)p53(-/-) mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008546
003      
CZ-PrNML
005      
20150331111255.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/onc.2013.414 $2 doi
035    __
$a (PubMed)24121269
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Basova, P $u 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Experimental Biomodels, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
245    10
$a Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice / $c P. Basova, V. Pospisil, F. Savvulidi, P. Burda, K. Vargova, L. Stanek, M. Dluhosova, E. Kuzmova, A. Jonasova, U. Steidl, P. Laslo, T. Stopka,
520    9_
$a PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1(ure/ure) mice (PU.1(ure/ure)p53(-/-)) results in more aggressive AML with shortened overall survival. PU.1(ure/ure)p53(-/-) progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1(ure/ure)p53(-/-) mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x genetika $x patologie $7 D015470
650    _2
$a játra $x patologie $7 D008099
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    _2
$a onkogenní proteiny v-myb $x genetika $x metabolismus $7 D020626
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    _2
$a protoonkogenní proteiny c-myc $x genetika $x metabolismus $7 D016271
650    _2
$a slezina $x patologie $7 D013154
650    _2
$a trans-aktivátory $x genetika $7 D015534
650    _2
$a aktivace transkripce $7 D015533
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pospisil, V $u Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Savvulidi, F $u Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Burda, P $u Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Vargova, K $u Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Stanek, L $u 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Pathology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Dluhosova, M $u Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kuzmova, E $u Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Jonasova, A $u 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Medicine-Haematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Steidl, U $u Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA.
700    1_
$a Laslo, P $u Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, St James's University Hospital, University of Leeds, Leeds, UK.
700    1_
$a Stopka, T $u 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Medicine-Haematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00003600 $t Oncogene $x 1476-5594 $g Roč. 33, č. 39 (2014), s. 4735-45
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24121269 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150331111525 $b ABA008
999    __
$a ok $b bmc $g 1065819 $s 891346
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 33 $c 39 $d 4735-45 $i 1476-5594 $m Oncogene $n Oncogene $x MED00003600
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Možnosti archivace